IRIS
PETRACCA, MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.518
NA - Nord America 2.617
EU - Europa 2.443
SA - Sud America 374
AF - Africa 105
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.069
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.489
SG - Singapore 1.453
RU - Federazione Russa 983
CN - Cina 725
IT - Italia 638
VN - Vietnam 629
BR - Brasile 289
DE - Germania 288
HK - Hong Kong 276
FR - Francia 105
NL - Olanda 91
IN - India 81
GB - Regno Unito 80
JP - Giappone 70
CA - Canada 67
FI - Finlandia 58
KR - Corea 54
UA - Ucraina 49
BD - Bangladesh 40
MX - Messico 34
ZA - Sudafrica 30
IE - Irlanda 28
AR - Argentina 27
CI - Costa d'Avorio 27
PH - Filippine 23
PL - Polonia 23
IQ - Iraq 22
ES - Italia 20
TH - Thailandia 18
ID - Indonesia 17
SE - Svezia 17
EC - Ecuador 15
TW - Taiwan 15
SA - Arabia Saudita 14
TR - Turchia 14
LT - Lituania 11
CO - Colombia 10
PK - Pakistan 10
BE - Belgio 9
PE - Perù 9
AT - Austria 8
JO - Giordania 7
MA - Marocco 7
MY - Malesia 7
TN - Tunisia 7
UZ - Uzbekistan 7
VE - Venezuela 7
AU - Australia 6
EG - Egitto 6
CL - Cile 5
CZ - Repubblica Ceca 5
NP - Nepal 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
CH - Svizzera 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
IL - Israele 4
IR - Iran 4
KE - Kenya 4
NZ - Nuova Zelanda 4
TT - Trinidad e Tobago 4
AL - Albania 3
AM - Armenia 3
MN - Mongolia 3
NG - Nigeria 3
OM - Oman 3
PT - Portogallo 3
PY - Paraguay 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
GR - Grecia 2
HR - Croazia 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
NI - Nicaragua 2
PA - Panama 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
AD - Andorra 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BF - Burkina Faso 1
CG - Congo 1
CU - Cuba 1
CY - Cipro 1
DM - Dominica 1
EE - Estonia 1
GE - Georgia 1
HT - Haiti 1
Totale 9.056
Salva come PNG Salva come JPEG
Città #
Singapore 750
San Jose 547
Ashburn 319
Hong Kong 261
Hefei 250
Moscow 237
Beijing 194
Ho Chi Minh City 192
Santa Clara 156
Hanoi 139
Naples 138
Chandler 117
Los Angeles 101
Amsterdam 67
Tokyo 65
Lauterbourg 61
Munich 54
Council Bluffs 52
Seoul 43
Dallas 42
New York 38
Milan 35
Napoli 35
São Paulo 34
Buffalo 33
Krefeld 33
Millbury 32
Boston 31
Orem 28
Frankfurt am Main 27
Da Nang 26
Redondo Beach 26
Helsinki 25
Montreal 25
The Dalles 25
Lawrence 24
Des Moines 20
Haiphong 20
London 20
Chicago 19
Falkenstein 19
Chennai 18
Dublin 18
Seattle 18
Rome 17
Atlanta 16
Denver 16
Johannesburg 16
Mexico City 16
Warsaw 16
Rottweil 15
Toronto 15
Poplar 13
Stockholm 13
Turku 13
Houston 12
Nanjing 12
Princeton 12
Baghdad 11
Biên Hòa 11
Brooklyn 11
Ottawa 11
Mumbai 10
Phoenix 10
Pune 10
Tianjin 10
Wilmington 10
Boardman 9
Lappeenranta 9
Washington 9
Bangkok 8
Belo Horizonte 8
Brussels 8
Dong Ket 8
Manchester 8
Norwalk 8
Porto Alegre 8
Rio de Janeiro 8
Bắc Giang 7
Can Tho 7
Kyiv 7
Paris 7
Shanghai 7
Tashkent 7
Amman 6
Ankara 6
Augusta 6
Bari 6
Charlotte 6
Hải Dương 6
Marano 6
Shenzhen 6
Thái Bình 6
Udine 6
Vicenza 6
Vĩnh Long 6
Arcore 5
Bologna 5
Brasília 5
Campinas 5
Totale 4.935
Salva come PNG Salva come JPEG
Nome #
Neurologia per le professioni sanitarie 276
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 275
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 177
GBA-Related Parkinson’s Disease:Dissection of Genotype–Phenotype Correlates in a LargeItalian Cohort 171
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 167
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 160
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 155
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 154
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 151
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 148
Signs and symptoms of COVID-19 in patients with multiple sclerosis 147
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 145
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 143
The Italian Dystonia Registry: rationale, design and preliminary findings 141
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 141
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 140
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 139
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 138
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 138
Cerebellar lobule atrophy and disability in progressive MS 138
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 135
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 135
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 134
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice 131
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 130
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 130
Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak 130
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 129
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 129
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 129
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 127
MR Imaging Signs of Gadolinium Retention Are Not Associated with Long-Term Motor and Cognitive Outcomes in Multiple Sclerosis 126
Idiopathic late-onset cerebellar ataxia with cerebellar atrophy in a patient diagnosed with Chiari I malformation: a case report. 126
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 125
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 124
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate. 119
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 119
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 118
Multiple sclerosis and systemic sclerosis: efficacy of interferon beta on skin lesions. 118
Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy? 117
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 117
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 115
Sporadic Porphyria Cutanea Tarda in a Patient with Multiple Sclerosis Treated with Interferon Beta 1-a Therapy: A Case Report. 113
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis 112
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 111
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis 110
Efficacy of levetiracetam in hemifacial spasm: a case report. 110
Tolosa-Hunt syndrome in a patient with autoimmune hemolytic anemia. 109
Integration of the expanded disability status scale with ambulation, visual and cognitive tests 107
Quantitative MRI in Multiple Sclerosis: From Theory to Application 107
The management of multiple sclerosis by reference centers in south of Italy: a 2011 survey on health demands and needs in Campania region 107
Spread of dystonia in patients with idiopathic adult-onset laryngeal dystonia 107
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 103
Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia 102
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 101
Association between CD20+ T lymphocytes and neuropsychological findings in multiple sclerosis 101
Walk your talk: Real-world adherence to guidelines on the use of MRI in multiple sclerosis 98
Adult onset Rasmussen’s Encephalitis: a case report. 96
Glossopharyngeal neuralgia as onset of multiple sclerosis. 94
Low serum 25‑hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosis 89
Prevalence and Incidence of Paramagnetic Rim Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis 89
Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis 87
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy) 86
Retinal and choriocapillary vascular changes in early stages of multiple sclerosis: A prospective study 86
Prevalence of autoimmine thyroiditis In an Italian multiple sclerosis cohort 81
Disability outcomes in early-stage African American and White people with multiple sclerosis 77
Cerebellum and neurodegenerative diseases: Beyond conventional magnetic resonance imaging 68
Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis 67
The development of subcortical gray matter atrophy in multiple sclerosis: One size does not fit all 63
Unraveling deep gray matter atrophy and iron and myelin changes in multiple sclerosis 62
Neuroimaging correlates of cognitive dysfunction in adults with multiple sclerosis 59
An MRI evaluation of grey matter damage in African Americans with MS 54
Dysarthria assessment in multiple sclerosis patients 40
Predicting 10-Year Clinical Outcomes in MS with Radiomics-Based Machine Learning Models 36
Low serum 25‑hydroxy-vitamin D levels are associated with cognitive impairment in multiple sclerosis 33
null 33
Anti-EBV antibody reduction during ocrelizumab treatment is not associated with multiple sclerosis outcomes 32
Plasma Neurofilament Light Chain Is Associated with Cognitive Functions but Not Patient-Reported Outcomes in Multiple Sclerosis 27
Plasma neurofilament light chain to evaluate response during cladribine treatment in multiple sclerosis 27
Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis 27
Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis 24
Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: A real-world, multi-center, propensity score-matched study 20
A proof-of-concept study on the effectiveness of botulinum toxin on spasticity plus syndrome in multiple sclerosis 19
null 15
Totale 9.233
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.211
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.211
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202115 0 0 0 0 0 0 0 0 0 0 0 15
2021/2022267 14 5 10 9 6 21 9 11 26 17 54 85
2022/2023562 42 49 11 9 39 64 151 26 61 57 36 17
2023/2024432 15 61 42 37 26 77 15 44 18 9 52 36
2024/20252.370 104 97 17 47 78 167 236 163 136 214 877 234
2025/20265.241 475 458 559 563 894 175 486 384 640 390 193 24
Totale 9.233